Inovio Pharmaceuticals, Inc. (NASDAQ:INO) received a $13.00 price target from equities researchers at HC Wainwright in a report released on Thursday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s target price points to a potential upside of 118.86% from the company’s current price.

INO has been the topic of a number of other reports. Aegis reissued a “buy” rating and issued a $14.00 price objective on shares of Inovio Pharmaceuticals in a research report on Tuesday, July 18th. Maxim Group increased their price objective on shares of Inovio Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Wednesday, May 24th. ValuEngine raised shares of Inovio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, June 2nd. Stifel Nicolaus reissued a “buy” rating and issued a $11.00 price objective on shares of Inovio Pharmaceuticals in a research report on Tuesday, April 25th. Finally, Zacks Investment Research downgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, April 17th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the company. Inovio Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $19.90.

Shares of Inovio Pharmaceuticals (NASDAQ INO) opened at 5.94 on Thursday. Inovio Pharmaceuticals has a 52 week low of $5.83 and a 52 week high of $11.00. The firm has a 50-day moving average of $7.65 and a 200 day moving average of $6.92. The firm’s market capitalization is $443.28 million.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($0.31) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.31). Inovio Pharmaceuticals had a negative net margin of 235.91% and a negative return on equity of 65.97%. The company had revenue of $10.40 million for the quarter, compared to the consensus estimate of $5.83 million. During the same period in the prior year, the firm posted ($0.11) EPS. The company’s quarterly revenue was up 28.4% compared to the same quarter last year. On average, equities research analysts expect that Inovio Pharmaceuticals will post ($1.11) EPS for the current fiscal year.

WARNING: This piece was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece on another site, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/07/27/inovio-pharmaceuticals-inc-nasdaqino-given-a-13-00-price-target-at-hc-wainwright.html.

In related news, Director David B. Weiner sold 8,000 shares of the stock in a transaction on Thursday, May 25th. The shares were sold at an average price of $8.00, for a total value of $64,000.00. Following the transaction, the director now directly owns 740,956 shares of the company’s stock, valued at approximately $5,927,648. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 10.60% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Private Capital Advisors Inc. bought a new position in Inovio Pharmaceuticals during the second quarter worth approximately $274,000. Credit Suisse AG increased its position in Inovio Pharmaceuticals by 108.6% in the first quarter. Credit Suisse AG now owns 132,688 shares of the biopharmaceutical company’s stock worth $879,000 after buying an additional 69,068 shares during the period. Metropolitan Life Insurance Co. NY increased its position in Inovio Pharmaceuticals by 8.5% in the first quarter. Metropolitan Life Insurance Co. NY now owns 51,573 shares of the biopharmaceutical company’s stock worth $341,000 after buying an additional 4,020 shares during the period. Bank of America Corp DE increased its position in Inovio Pharmaceuticals by 14.6% in the first quarter. Bank of America Corp DE now owns 28,256 shares of the biopharmaceutical company’s stock worth $188,000 after buying an additional 3,605 shares during the period. Finally, Schwab Charles Investment Management Inc. increased its position in Inovio Pharmaceuticals by 5.8% in the first quarter. Schwab Charles Investment Management Inc. now owns 305,844 shares of the biopharmaceutical company’s stock worth $2,025,000 after buying an additional 16,845 shares during the period. 27.77% of the stock is currently owned by hedge funds and other institutional investors.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Analyst Recommendations for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.